###begin article-title 0
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 292 301 292 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 219 224 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 272 277 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 369 374 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 579 584 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcription of HIV-1 genes is activated by HIV-1 Tat protein, which induces phosphorylation of RNA polymerase II (RNAPII) C-terminal domain (CTD) by CDK9/cyclin T1. Earlier we showed that CDK2/cyclin E phosphorylates HIV-1 Tat in vitro. We also showed that CDK2 induces HIV-1 transcription in vitro and that inhibition of CDK2 expression by RNA interference inhibits HIV-1 transcription and viral replication in cultured cells. In the present study, we analyzed whether Tat is phosphorylated in cultured cells by CDK2 and whether Tat phosphorylation has a regulatory effect on HIV-1 transcription.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 46 55 46 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 83 86 83 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 246 248 246 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 529 536 529 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 558 561 558 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 568 571 568 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 615 622 615 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 639 642 639 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 649 652 649 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 908 910 908 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 917 920 917 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 925 927 925 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46</sup>
###xml 930 933 930 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 965 968 965 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 975 978 975 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 983 986 983 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 1045 1048 1045 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 676 681 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 766 771 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 847 852 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1091 1096 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We analyzed HIV-1 Tat phosphorylation by CDK2 in vitro and identified Ser16 and Ser46 residues of Tat as potential phosphorylation sites. Tat was phosphorylated in HeLa cells infected with Tat-expressing adenovirus and metabolically labeled with 32P. CDK2-specific siRNA reduced the amount and the activity of cellular CDK2 and significantly decreased phosphorylation of Tat. Tat co-migrated with CDK2 on glycerol gradient and co-immunoprecipitated with CDK2 from the cellular extracts. Tat was phosphorylated on serine residues in vivo, and mutations of Ser16 and Ser46 residues of Tat reduced Tat phosphorylation in vivo. Mutation of Ser16 and Ser46 residues of Tat reduced HIV-1 transcription in transiently transfected cells. The mutations of Tat also inhibited HIV-1 viral replication and Tat phosphorylation in the context of the integrated HIV-1 provirus. Analysis of physiological importance of the S16QP(K/R)19 and S46YGR49 sequences of Tat showed that Ser16 and Ser46 and R49 residues are highly conserved whereas mutation of the (K/R)19 residue correlated with non-progression of HIV-1 disease.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 174 179 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results indicate for the first time that Tat is phosphorylated in vivo; Tat phosphorylation is likely to be mediated by CDK2; and phosphorylation of Tat is important for HIV-1 transcription.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 395 396 395 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 836 837 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 840 847 840 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1281 1283 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1504 1505 1504 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1506 1508 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1509 1511 1509 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1546 1548 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1549 1551 1549 1551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1633 1634 1633 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1635 1637 1635 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1638 1640 1638 1640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1717 1719 1717 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1720 1722 1720 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1861 1863 1861 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1864 1866 1864 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 2060 2062 2060 2062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2177 2179 2177 2179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2351 2353 2351 2353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 2567 2576 2567 2576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2577 2579 2577 2579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2590 2598 2590 2598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2599 2601 2599 2601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 2648 2656 2648 2656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 2770 2772 2770 2772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2892 2901 2892 2901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2902 2904 2902 2904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 3011 3020 3011 3020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 3021 3023 3021 3023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 3093 3101 3093 3101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 4 39 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 354 359 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 699 704 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 922 927 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1300 1305 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1577 1582 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1617 1622 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1701 1706 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2534 2539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2604 2609 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
###xml 3173 3178 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The human immunodeficiency virus type 1 (HIV-1) requires host cell factors for all steps of the viral replication [1,2]. Recently, multiple covalent modifications of viral proteins that regulate virus-host protein interactions have been described, such as phosphorylation, acetylation and ubiquitination. Phosphorylation has been reported for almost all HIV-1 accessory proteins, including Vpu [3], Vpr [4], Vif [5], Nef [6], and Rev [7]. Transcription of HIV-1 viral genes is induced by a viral transactivator protein (Tat) [1,2]. The activation domain of Tat (amino acids 1-48) interacts with host cell factors, whereas the positively charged RNA-binding domain (amino acids 49-57) interacts with HIV-1 transactivation response (TAR) RNA [1,2]. In cell-free transcription assays Tat induces exclusively elongation of transcription [8,9]. In vivo, Tat additionally induces initiation of transcription from the integrated HIV-1 promoter [10-12]. Tat stimulates formation of transcription complex containing TATA-box-binding protein (TBP) but not TBP-associated factors (TAFs), thus indicating that Tat may enhance initiation of transcription [10], apparently in agreement with the earlier observation that Tat binds directly to the TBP-containing basal transcription factor TFIID [13]. Tat activates HIV-1 transcription by recruiting transcriptional co-activators that include Positive Transcription Elongation Factor b (P-TEFb), containing CDK9/cyclin T1; an RNA polymerase II C-terminal domain kinase [9,14,15] and histone acetyl transferases [16-18]. Whereas P-TEFb induces HIV-1 transcription from non-integrated HIV-1 template [9,14,15], histone acetyl transferases allow induction of integrated HIV-1 provirus [16-18]. Additional CTD kinases, including CDK2 and CDK7 were also reported to be activated by Tat and to induce functional CTD phosphorylation [19,20]. Tat itself is a subject for covalent modifications by host cell proteins. Tat is directly acetylated at lysine 28, within the activation domain, and lysine 50, in the TAR RNA binding domain [21]. Tat is also ubiquitinated at lysine 71 and its ubiquitination stimulates the transcriptional properties of Tat [22]. Recently, Tat was shown to be methylated by the arginine methyltransferase, PRMT6 and the arginine methylation of Tat negatively regulated its transcriptional activity [23]. Surprisingly, in spite of the interaction of Tat with P-TEFb and probably other kinases and its involvement in multiple protein phosphorylation reactions, the phosphorylation of HIV-1 Tat has only been reported in vitro [24], but not in vivo [25]. HIV-2 Tat was reported to be phosphorylated in vivo presumably by CDK9, but this phosphorylation was not important for Tat-2 function as a transcriptional activator [26]. We previously reported that Tat dynamically interacts with CDK2/cyclin E and is also phosphorylated by CDK2/cyclin E in vitro [20]. This dynamic interaction greatly stimulated the activity of CDK2/cyclin E toward phosphorylation of CTD in vitro [20]. In the present study we investigated whether Tat is phosphorylated in vivo and whether this phosphorylation has a regulatory role in Tat-activated HIV-1 transcription.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Tat is phosphorylated by CDK2 in vitro and Ser-16 and Ser-46 residues of Tat are potential phosphorylation sites
###end title 11
###begin p 12
###xml 77 86 77 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 542 543 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 544 545 544 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 546 547 546 547 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 552 554 552 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 697 699 697 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 706 709 706 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 712 714 712 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46</sup>
###xml 717 720 717 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 723 725 723 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">68</sup>
###xml 728 731 728 731 <sup xmlns:xlink="http://www.w3.org/1999/xlink">71 </sup>
###xml 798 807 798 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 935 944 935 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1215 1217 1215 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1378 1380 1378 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1711 1713 1708 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1748 1749 1745 1746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 2278 2287 2275 2284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 2348 2351 2345 2348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 2357 2360 2354 2357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 2377 2379 2374 2376 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 2382 2385 2379 2382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 2390 2392 2387 2389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46</sup>
###xml 2395 2398 2392 2395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 2494 2496 2491 2493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
We previously showed that Tat is phosphorylated by recombinant CDK2/cyclin E in vitro and that Tat's Ser16 was a potential phosphorylation site [20]. Indeed recombinant CDK2/cyclin E efficiently phosphorylates Tat (Fig. 1A, lane 1). Tat can also be phosphorylated by HeLa nuclear extract (Fig. 1A, lane 2). Immunodepletion of CDK2 from HeLa nuclear extract completely abolished Tat phosphorylation (Fig. 1A, lane 3) suggesting that under these conditions Tat was largely phosphorylated by CDK2. Upon analysis of the sequence of Tat, the (S/T)0P1K2(K/R)3 consensus motif for serine phosphorylation by CDK2 [27,28] was not found, but several sequences were found that partially matched this motif: S16QP(K/R)19 , S46YGR49 , S68LSK71 . To determine potential phosphorylation sites, Tat phosphorylated in vitro was analyzed by Mass spectrometry. For this purpose, purified recombinant Tat was phosphorylated with recombinant CDK2/cyclin E in vitro followed by immunoprecipitation, SDS-PAGE purification, in-gel digestion with trypsin, and HPLC purification. Analysis of HPLC eluates showed presence of two peaks in the digest generated from phosphorylated Tat that were absent in digest of non-phosphorylated Tat (Fig. 1B). These two peaks were collected and subjected to MALDI-TOF mass spectrometry. Masses of the peptides over 900 Da were acquired and analyzed with FindPep tool [29] using the sequence of Tat (MEPVDPNLEPWKHPGSQPRTACNNCYCKKCCFHCYACFTRKGLGISYGRKKRRQRRRAPQDSQTHQASLSKQ) as input. The masses of peptides that did not match to Tat were further compared with Tat peptides from which we subtracted 18 Da, assuming beta-elimination of phosphoric acid which is likely to occur during MALDI-TOF analysis [30]. Matched peptides shown in Table 1, indicate that Peak I contains peptides with Serine 46 as a potential phosphorylation site, whereas Peak II contains peptides with Serine 16 as a potential phosphorylation site. All matched peptides contain internal lysine or arginine residues, and thus they are apparently products of incomplete digestion by trypsin, which could be a result of incomplete in-gel digestion. Also acquisition of peptide with masses over 900 Da would only allow detection of relatively large peptides. The data suggest that Tat is phosphorylated in vitro by CDK2 and that this phosphorylation might take place at Ser16 or Ser46 residues within S16QPR19 and S46YGR49 sequences that partially match to the (S/T)Px(K/R) consensus sequence for CDK2 phosphorylation [28].
###end p 12
###begin p 13
Determination of sites of phosphorylation in Tat
###end p 13
###begin p 14
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Analysis of HIV-1 Tat phosphorylated by CDK2/cyclin E <italic>in vitro</italic></bold>
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 64 96 64 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>, Tat is phosphorylated by CDK2</bold>
###xml 133 142 133 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 414 415 414 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 414 469 414 469 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic>, HPLC profiles of Tat peptides after trypsin cleavage</bold>
###xml 506 515 506 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 724 730 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">No Tat</italic>
###xml 765 768 764 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tat</italic>
###xml 804 817 803 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(Phospho)-Tat</italic>
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of HIV-1 Tat phosphorylated by CDK2/cyclin E in vitro. A, Tat is phosphorylated by CDK2. Recombinant Tat was phosphorylated in vitro by purified CDK2/cyclin E (lane 1), by HeLa nuclear extract (lane 2) or by CDK2-depleted HeLa nuclear extract (lane 3). Tat was resolved by 12% SDS Tris-Tricin PAGE. The gel was stained with Coomassie blue (upper panel) and exposed to Phospho Imager screen (lower panel). B, HPLC profiles of Tat peptides after trypsin cleavage. Recombinant Tat was phosphorylated in vitro by purified CDK2/cyclin E, resolved by 12% SDS Tris-Tricin PAGE, and subjected to in-gel trypsin digestion. The eluted peptides were resolved by reverse phase chromatography on muRPC C2/C18 ST 4.6/100 column. No Tat, mock trypsin digest without Tat. Tat, digest of non-phosphorylated Tat. (Phospho)-Tat, digestion of phosphorylated Tat. I and II, peaks identified in the elution profile of phosphorylated Tat that were subjected to MALDI TOF/TOF mass spectrometry.
###end p 14
###begin title 15
Tat is phosphorylated in cultured cells
###end title 15
###begin p 16
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 675 677 675 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1194 1196 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1294 1296 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1593 1595 1593 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1727 1729 1727 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1734 1736 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1820 1828 1820 1828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Previous attempts to detect Tat phosphorylation in vivo were unsuccessful [25]. We hypothesized that low level of Tat expression after transfection and/or rapid de-phosphorylation by cellular phosphatases might prevent detection of Tat phosphorylation in vivo. To overcome these difficulties, we expressed Flag-tagged Tat which we found to be expressed to a higher level in COS-7 cells than untagged Tat (Fig. 2, compare lanes 3 and 4). To facilitate expression of Flag-Tat in HeLa cells we used adenovirus-mediated expression of Tat [31]. HeLa cells were infected with Adeno-Tat and incubated 48 hours post infection to allow expression of Tat. Then cells were pulsed with (32P)-labeled orthophosphate, and Tat was immunoprecipitated from cellular lysates using monoclonal anti-Flag or polyclonal anti-Tat antibodies. Immunoprecipitated proteins were resolved by SDS-PAGE on 15% Tris-Tricine gel [32] and transferred to PVDF membrane. The membrane was probed with monoclonal anti-Tat antibodies (Fig. 3A) using 3,3'-Diaminobenzidine enhancer system (DABM, Sigma), and also exposed to a PhosphoImager screen (Fig. 3B). Both antibodies precipitated a well detectable amount of Tat protein (Fig. 3A, lanes 3, 4, 6 and 7). Under these experimental conditions, Tat was phosphorylated (Figs. 3B and 3C, compare lane 3 to lane 1 and lane 6 to lane 5). Next we treated cells with okadaic acid, an inhibitor of PPP-type phosphatases, to prevent rapid dephosphorylation of Tat in the cells and during the lysis procedure. Treatment with okadaic acid did not change the amount of precipitated Tat (Fig. 3A, lanes 3, 4, 6 and 7). In contrast, Tat phosphorylation was significantly enhanced when cells were treated with okadaic acid (Figs.3B and 3C, lanes 4 and 7). Taken together, these results indicate that Tat is phosphorylated in vivo and that Tat phosphorylation is enhanced when cells are treated with the inhibitor of PPP-phosphatases.
###end p 16
###begin p 17
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of untagged and Flag-tagged Tat</bold>
###xml 273 279 <span type="species:ncbi:9986">rabbit</span>
Expression of untagged and Flag-tagged Tat. COS-7 cells were transfected with Tat (lane 3) and Flag-tagged Tat (lane 4) expression vectors or mock-transfected (lane 2). At 48 hours post transfection cells were lysed and Tat was immediately immunoprecipitated with anti-Tat rabbit polyclonal antibodies (lanes 2-4). Immunoprecipitated Tat was resolved by 15% Tris-Tricine SDS-PAGE, transferred to polyvinylidene fluoride membrane and immunoblotted with anti-Tat monoclonal antibodies using the 3,3'-diaminobenzidine enhancer system. Positions of Tat and Flag-Tat are indicated. Lane 1, prestained 10 kDa molecular weight markers.
###end p 17
###begin p 18
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIV-1 Tat is phosphorylated in cultured cells</bold>
###xml 272 274 272 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 680 681 679 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 795 796 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 850 851 849 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 465 471 <span type="species:ncbi:9986">rabbit</span>
###xml 530 536 <span type="species:ncbi:10090">murine</span>
###xml 966 971 <span type="species:ncbi:10090">mouse</span>
HIV-1 Tat is phosphorylated in cultured cells. HeLa cells were infected with recombinant adenovirus expressing Flag-tagged Tat as described in Methods (lanes 3, 4, 6 and 7). Lanes 1, 2, and 5 - control uninfected cells. At 48 hours post infection cells were labeled with (32P)-orthophosphate for 2 hours without (lanes 1, 3 and 6) or with (lanes 2, 4, 5 and 7) 1 muM okadaic acid (OA). Whole cell extracts were prepared and Tat was immunoprecipitated with anti-Tat rabbit polyclonal antibodies (lanes 1-4) or anti-Flag monoclonal murine antibodies (lanes 5-7). Immunoprecipitated Tat was resolved by 15% Tris-Tricine SDS-PAGE, and transferred to polyvinylidene fluoride membrane. A, immunoblot of the membrane with anti-Tat monoclonal antibodies using the 3,3'-diaminobenzidine enhancer system. B, autoradiography of the membrane on Phosphor Imager. C, quantification of panel B. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by anti-mouse HRP-conjugated secondary antibodies is indicated by asterisk.
###end p 18
###begin title 19
CDK2 phosphorylates Tat in cultured cells
###end title 19
###begin p 20
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 1097 1099 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1177 1179 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1314 1316 1310 1312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1451 1455 1447 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A,B</xref>
###xml 1460 1462 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1739 1740 1735 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1796 1797 1792 1793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1892 1893 1888 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 2119 2120 2115 2116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 2210 2211 2206 2207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 2424 2426 2420 2422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 2465 2467 2461 2463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 2558 2560 2554 2556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 2647 2649 2643 2645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7A</xref>
###xml 2815 2817 2811 2813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7B</xref>
###xml 2902 2904 2898 2900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 3052 3054 3048 3050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
###xml 3121 3123 3117 3119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7C</xref>
We next investigated whether Tat phosphorylation was mediated by CDK2 in vivo using CDK2-directed RNA interference [33]. HeLa cells were infected with Adeno-Tat and subsequently transfected with siRNAs against CDK2. Transfection of HeLa cells with siRNAs against CDK2 decreased the level of expression of CDK2 by 2.5-fold (Figs. 4A and 4B, lane 3). A control non-targeting siRNA pool did not affect expression of CDK2 (Figs. 4A and 4B, lane 2). The non-targeting siRNA control was used to ensure that transfection itself did not affect CDK2 expression. Western blot analysis of tubulin and CDK9 was used as control for the specificity of siRNAs. As shown in Fig. 4A transfection with both siRNAs did not affect the level of alpha-tubulin expression. To ensure that CDK2-directed siRNA decreased the enzymatic activity of cellular CDK2, CDK2 was immunoprecipitated from cells transfected with non-targeting or CDK2-directed siRNA and assayed for its enzymatic activity using recombinant Tat as a substrate. The activity of CDK2 was decreased in the cells transfected with CDK2-directed siRNA (Fig. 4C, lane 2) as compared to the cells transfected with non-targeting siRNA (Fig. 4C, lane 1). Next the cells were infected with Adeno-Tat, transfected with non-targeting or CDK2-directed siRNAs and pulse-labeled with (32P). In this experiment no okadaic acid was used. Inhibition of CDK2 by siRNA reduced the level of Tat phosphorylation by 3-fold (Figs. 5A,B and 5C, compare lanes 2 and 3). Thus CDK2 is likely to mediate Tat phosphorylation in cultured cells. To analyze whether Tat and CDK2 might be present in the same molecular weight complex, we analyzed sedimentation of Tat and CDK2 by ultracentrifugation on a glycerol gradient (Fig. 6). Both Tat and CDK2 co-migrated in fractions 1-8 (Fig. 6). The CDK9 was present in most of the fractions with the peak in fractions 4-5 and 9-10 (Fig. 6), which is likely to correspond to low and high molecular weight P-TEFb complexes. HEXIM1, and Brd4 were mostly present in fractions 2-6, although HEXIM1 was also detected in higher molecular weight fractions 10 and 11 (Fig. 6). Neither Tat nor CDK2 co-migrated with RNAPII which was present in fractions 1-13 (Fig. 6). We further analyzed association of Tat with CDK2 by immunoprecipitation. Flag-Tat was expressed in HeLa cells by infection with Adeno-Tat and precipitated from cellular extracts with anti-Flag antibodies (Fig. 7A). CDK2 co-precipitated with Tat (Fig. 7A, lane 4). CDK2 was not precipitated with anti-Tat antiserum from non-infected cells (Fig. 7A, lane 3) or not with non-specific preimmune serum from adeno-Tat infected cells (Fig. 7A, lane 5). Inhibition of CDK2 expression by CDK2-specific RNAi significantly reduced CDK2 co-precipitated to Tat apparently due reduction of the expressed CDK2 (Fig. 7B, compare lane 4 to lane 2). Association of Tat with CDK9 was slightly reduced (Fig. 6B) but this reduction correlated to the decreased amount of Tat precipitated by anti-Flag antibodies. Binding of Tat-cyclin T1 was not reduced (Fig. 7C, lanes 3 and 5). The cyclin T2 did not precipitate with Tat (Fig. 7C), which indicated a specificity of the immunoprecipitation. Taking together, these results suggest that CDK2 associates with Tat in cultured cells, and that inhibition of CDK2 expression prevents Tat phosphorylation. Thus, CDK2 is likely to phosphorylate Tat directly in cultured cells.
###end p 20
###begin p 21
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CDK2-directed siRNA inhibits CDK2 expression</bold>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 46 47 46 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 445 446 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 553 554 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 933 935 921 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 807 813 <span type="species:ncbi:9986">rabbit</span>
###xml 863 869 <span type="species:ncbi:9986">rabbit</span>
CDK2-directed siRNA inhibits CDK2 expression. A, CDK2-directed siRNA inhibits expression of CDK2. HeLa cells were transfected with siRNAs targeting CDK2 (lane 3) or non-targeting control pool (control, lane 2). Lane 1, untransfected cells. At 48 hours post-transfection cells were lysed and cellular extracts were resolved on 12% Tris-Tricine SDS-PAGE and analyzed by immunoblotting analysis with antibodies against CDK2, CDK9 or alpha-tubulin. B, quantification of the CDK2 expression in panel A using alpha-tubulin expression level for normalization. C, CDK2-directed siRNA inhibits enzymatic activity of CDK2. CDK2 was precipitated from cellular extracts prepared from HeLa cells transfected with siRNAs targeting CDK2 (lane 2) or non-targeting control (lanes 1 and 3). Lanes 1 and 2, precipitation with rabbit anti-CDK2 antibodies. Lane 3, precipitation with rabbit preimmune serum. Immunoprecipitates were incubated with gamma-(32P)ATP and recombinant Tat (see Methods), resolved on 12% Tris-Tricine SDS-PAGE and analyzed by autoradiography on Phosphor Imager. Position of Tat is indicated.
###end p 21
###begin p 22
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CDK2-directed siRNA blocks Tat phosphorylation</bold>
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 310 312 310 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 518 519 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 633 634 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 695 696 695 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 854 859 <span type="species:ncbi:10090">mouse</span>
CDK2-directed siRNA blocks Tat phosphorylation. A, HeLa cells were infected with Adeno-Tat (lanes 2 and 3). At 4 hours post infection, cells were transfected with siRNAs targeting CDK2 (lane 3) or non-targeting control pool (lane 2). Lane 1 - control cells. At 48 hours post-infection cells were labeled with (32P)-orthophosphate for 2 hours. Whole cell extract was subjected to immunoprecipitation with anti-Flag antibodies, resolved by 15% Tris-Tricine SDS-PAGE, and transferred to polyvinylidene fluoride membrane. A, immunoblot of the membrane with anti-Tat monoclonal antibodies using the 3,3'-diaminobenzidine enhancer system. B, autoradiography of the membrane on Phosphor Imager screen. C, quantification of the panel B. Position of Tat is indicated by arrow. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by anti-mouse HRP-conjugated secondary antibodies is indicated by asterisk.
###end p 22
###begin p 23
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tat and CDK2 co-migrate on glycerol gradient</bold>
Tat and CDK2 co-migrate on glycerol gradient. 293T cell lysated from the cells infected with Adeno-Tat were fractionated on 10%-30% glycerol gradients by centrifugation and analyzed with indicated antibodies by Immunoblotting.
###end p 23
###begin p 24
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>, CDK2 associates with Tat in cultured cells</bold>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 691 751 691 751 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic>, CDK2-specific siRNA inhibits association of Tat with CDK2</bold>
###xml 1084 1085 1084 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1084 1156 1084 1156 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic>, CDK2-specific siRNA does not affect association of Tat with cyclin T1</bold>
###xml 526 531 <span type="species:ncbi:10090">mouse</span>
###xml 623 628 <span type="species:ncbi:10090">mouse</span>
A, CDK2 associates with Tat in cultured cells. Flag-tagged Tat was expressed in HeLa cells by Adeno-Tat infection and precipitated with anti-Flag antibodies from cellular lysate. Co-precipitated proteins were resolved on 12% Tris-Tricine PAGE and analyzed by immunoblotting analysis with anti-CDK2 and anti-Tat antibodies. Lane 1, input control without Tat. Lane 2, input control with Tat. Lanes 3 and 4, extract without or with Tat precipitated with anti-Flag antibodies. Lane 5, extract with Tat precipitated with preimmune mouse IgG. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by anti-mouse HRP-conjugated secondary antibodies is indicated by asterisk. B, CDK2-specific siRNA inhibits association of Tat with CDK2. Flag-tagged Tat was expressed in 293T cells by transfection (lanes 2 and 4). Cells were transfected with non-targeting (lanes 1 and 2) or CDK2-specific (lanes 3 and 4) siRNAs. Lysates were precipitated with anti-Flag antibodies, resolved on 12% Tris-Tricine PAGE and immunoblotted with anti-Tat, anti-CDK9 or anti-CDK2 antibodies. C, CDK2-specific siRNA does not affect association of Tat with cyclin T1. Flag-tagged Tat was expressed in 293T cells by transfection (lanes 3 and 5). Cells were transfected with non-targeting (lanes 2 and 3) or CDK2-specific (lanes 4 and 5) siRNAs. Lysates were precipitated with anti-Flag antibodies, resolved on 12% Tris-Tricine PAGE and immunoblotted with anti-Tat, anti-CDK9 or anti-CDK2 antibodies. Lane 1, input.
###end p 24
###begin title 25
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Tat is phosphorylated on serine residues in vivo
###end title 25
###begin p 26
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 429 450 429 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials and Methods</italic>
###xml 539 541 539 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8B</xref>
###xml 621 628 621 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
We next determined whether serine, threonine or tyrosine residues of Tat were phosphorylated in vivo. HeLa cells were infected with Adeno-Tat, labeled with (32P), and treated with okadaic acid to achieve a higher level of Tat phosphorylation. Tat was immunoprecipitated with anti-Flag antibody and resolved on 15% SDS Tris-Tricine PAGE (Fig. 8A, lane 1). Phosphoamino acid analysis of radioactive Tat extracted from the gel (see Materials and Methods) showed presence of phospho-serines but not phospho-threonines or phospho-tyrosines in (32P)-labeled Tat (Fig. 8B). Thus, only serine residues of Tat were phosphorylated in vivo.
###end p 26
###begin p 27
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">HIV-1 Tat is phosphorylated on S<sup>16 </sup>and S<sup>46 </sup>residues <italic>in vivo</italic></bold>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 61 62 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 160 167 160 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Methods</italic>
###xml 221 223 221 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 489 490 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 489 490 488 489 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 633 654 632 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials and Methods</italic>
###xml 928 929 927 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 945 948 944 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 953 956 952 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 983 990 982 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1221 1223 1220 1222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat is phosphorylated on S16 and S46 residues in vivo. A, HeLa cells were infected with recombinant adenovirus expressing Flag-tagged Tat as described in Methods. At 48 hours post infection cells were labeled with (32P)-orthophosphate for 2 hours with 1 muM okadaic acid (OA). Lane1, Flag-Tat was immunoprecipitated from whole cell extracts with anti-Flag antibodies and resolved by 15% Tris-Tricine SDS-PAGE. Lane 2, control mock-transfected cells. The picture is an autoradiogram. B, Tat peptides were eluted from the gel shown in panel A by overnight incubation with trypsin and subjected to acid hydrolysis as described in Materials and Methods. The hydrolyzed material was spotted on nitrocellulose plate and examined by two-dimensional thin layer electrophoresis and autoradiography. The indicated positions of non-radioactive phospho-amino acid standards were visualized by staining with 0.5% ninhydrin in ethanol. C, Mutations of S16 and S46 reduce Tat phosphorylation in vivo. 293T cells were transfected with vectors expressing Flag-tagged WT Tat (lane 2), Tat S16A (lane 3), Tat S46A (lane 4) or Tat S16,46A (lane 5). Lane 1, mock transfection. At 48 hours post-transfection the cells were labeled with (32P)-orthophosphate for 2 hours. Whole cell extract was subjected for immunoprecipitation with anti-Flag antibodies, resolved by 15% Tris-Tricine SDS-PAGE, and analyzed by Western blotting with polyclonal anti-Tat antibodies and on Phosphor Imager. Quantification is shown in the lower panel. Position of Tat is indicated by arrow.
###end p 27
###begin title 28
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 28 31 28 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Phosphorylation of S16 and S46 residues of Tat in vivo
###end title 28
###begin p 29
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8C</xref>
###xml 761 764 761 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 769 772 769 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 804 811 804 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
We next investigated a possibility that Tat might be phosphorylated on S16 or S46 residues in vivo. We generated mutants of Flag-Tat in which either or both Ser residues were substituted by Ala. 293T cells were transfected with WT and mutant Tat-expressing vectors, Tat was precipitated with anti-Flag antibodies and analyzed on 15% SDS Tris-Tricine PAGE followed by PhosphoImager analysis. Expression of Tat was verified by Western blotting (Fig. 8C). While we could detect phosphorylation of WT Tat (Fig. 8C, lane 2), the Tat S16A mutant and Tat S46A mutant were about 2-3 fold less phosphorylated (Fig. 8C, middle and lower panels, lanes 3 and 4). The Tat S16,46A double mutant was even less phosphorylated (Fig. 8C, lane 5). Our results indicate that both S16 and S46 are likely to be phosphorylated in vivo.
###end p 29
###begin title 30
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Contribution of S16 and S46 residues of Tat to HIV-1 transcription
###end title 30
###begin p 31
###xml 56 59 56 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 64 67 64 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 1066 1068 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 1263 1265 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 1296 1299 1296 1299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 1305 1308 1305 1308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 754 759 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 847 852 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 970 975 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next investigated the functional relevance of Tat's S16 and S46 residues in HIV-1 transcription. We generated mutants of Tat in which either or both Ser residues were substituted by Ala. To ensure expression of the mutants, COS-7 cells were transfected with WT and mutant Tat-expressing vectors and cellular lysates were analyzed on 15% SDS Tris-Tricine PAGE followed by Western blot with anti-Tat antibodies. As shown in Fig. 9A, all Tat mutants were expressed, with the level of expression of Tat mutants higher than the WT Tat. The higher expression level of non-tagged Tat mutants was a reproducible effect and was not a consequence of the difference in the amount of transfected DNA. The effect of Tat mutations on the ability of Tat to activate HIV-1 LTR promoter was analyzed in HeLa cells co-transfected with Tat-expression vectors and HIV-1 LTR-LacZ reporter plasmid (Fig. 9B). Non-mutated Tat (WT) increased the level of transcription by 400-fold (Fig 9B). HIV-1 transcription induction by the Tat S16A mutant was approximately 75% that of WT Tat (Fig. 9B), while transactivation by the Tat S46A mutant was about 2 times lower than with the WT Tat (Fig. 9B) and induction by the double S16, 46A Tat mutant was 3-times lower than that of WT Tat (Fig. 9B). Thus, mutation of either Ser16 or Ser46 of Tat interferes with the level of Tat-transactivation and mutation of both residues has an additive effect.
###end p 31
###begin p 32
###xml 16 19 16 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mutations of Ser<sup>16 </sup>and Ser<sup>46 </sup>of Tat reduce its transactivation potential</bold>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 74 75 74 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 397 398 397 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 274 280 <span type="species:ncbi:9986">rabbit</span>
###xml 437 442 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mutations of Ser16 and Ser46 of Tat reduce its transactivation potential. A, COS-7 cells were transfected with WT Tat, Tat S16A, Tat S46A or Tat S16,46A expression vectors. At 48 hours posttransfection, the cells were lysed. Tat was immunoprecipitated from the lysates with rabbit polyclonal antibodies, resolved by 15% Tris-Tricine SDS-PAGE and immunoblotted with monoclonal anti-Tat antibodies. B, HeLa cells were transfected with the HIV-1 LTR-LacZ expression vector alone (not shown here) and in combination with WT Tat, Tat S16A, Tat S46A or Tat S16,46A expression vectors. At 48 hours posttransfection, cells were lysed and analyzed for beta-galactosidase activity with ONPG.
###end p 32
###begin title 33
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 131 136 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Contribution of S16 and S46 residues of Tat to the HIV-1 viral production and Tat phosphorylation in the context of the integrated HIV-1 provirus
###end title 33
###begin p 34
###xml 835 838 835 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A</xref>
###xml 902 905 902 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10A</xref>
###xml 1018 1020 1018 1020 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1305 1308 1305 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10B</xref>
###xml 103 108 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 142 147 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 296 301 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 499 504 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 646 651 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 806 811 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1428 1433 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We determined whether mutations of Tat S16A and/or S46A have an effect on the ability of Tat to induce HIV-1 transcription from an integrated HIV-1 provirus. We used HLM-1 cells (AIDS Research and Reference Reagent Program) that were derived from HeLa-CD4+ cells containing an integrated copy of HIV-1 proviral genome with a Tat-defective mutation (termination linker at the first AUG). HLM-1 cells are negative for virus particle production, but can be induced to express high levels of infectious HIV-1 after transfection with Tat. We transfected the HLM-1 cells with wild type or mutant Tat vectors and tested supernatants for the presence of HIV-1 particles using p24 gag antigen ELISA at day 0, day 1, day 2, day 7 and day 14 posttransfection. Neither S16A nor S46A mutants of Tat efficiently induced HIV-1 viral production (Fig. 10A). The double S16, 46A mutant also had a reduced activity (Fig. 10A). To phosphorylate Tat during virus replication, we pulsed HLM-1 cells transfected with WT and mutant Tat with (32P) orthophosphate and also treated the cells with okadaic acid. Tat was immunoprecipitated with anti-Flag antibodies, resolved on 15% SDS PAGE and its phosphorylation was detected by PhosphoImager. While WT Tat was phosphorylated, the mutants were not phosphorylated efficiently (Fig. 10B). These data indicate that the S16A and S46A mutations of Tat interfere with the ability of Tat to activate integrated HIV-1 provirus, and prevent Tat phosphorylation during one round of viral replication.
###end p 34
###begin p 35
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 0 80 0 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic>, Mutations of S<sup>16 </sup>and S<sup>46 </sup>of Tat reduce its ability to induce viral production</bold>
###xml 485 486 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 510 513 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 485 585 485 585 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic>, Mutations of S<sup>16 </sup>and S<sup>46 </sup>of Tat inhibit Tat phosphorylation during one round of viral replication</bold>
###xml 759 761 759 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 145 150 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A, Mutations of S16 and S46 of Tat reduce its ability to induce viral production. HLM1 is a HeLa derived cells containing one copy of integrated HIV-1 proviral genome with a Tat-defective mutation. Various Flag-tagged Tat (WT Tat, Tat S16A, Tat S46A or Tat S16,46A) expression vectors were used for HLM-1 transfections. Cells were cultured in complete media in absence of G418 for 14 days. The supernatants were collected at Day 0, 1, 2, 7 and 14, and analyzed for p24 by ELISA assay. B, Mutations of S16 and S46 of Tat inhibit Tat phosphorylation during one round of viral replication. HLM1 cells were transfected with vectors expressing Flag-tagged Tat (WT Tat, Tat S16A, Tat S46A or Tat S16,46A). At 48 hours post transfection the cells were labeled with (32P)-orthophosphate for 2 hours with 1 muM okadaic acid. Flag-Tat was immunoprecipitated from whole cell extracts with anti-Flag antibodies and resolved by 15% Tris-Tricine SDS-PAGE. The gel was dried and exposed to Phosphor Imager screen. Lane 1, Wt Tat. Lane 2, Tat S16A. Lane 3, Tat S46A. Lane 4, Tat S16,46A. Lane 5, mock-transfected cells. The picture is an autoradiogram.
###end p 35
###begin title 36
###xml 95 98 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 108 114 <span type="species:ncbi:9606">humans</span>
Correlation of mutations in putative CDK2 recognition sites on Tat with disease progression in HIV infected humans
###end title 36
###begin p 37
###xml 84 85 84 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 94 96 94 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 215 217 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 225 228 225 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 230 233 230 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 237 240 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 242 244 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">68</sup>
###xml 248 251 248 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink">71 </sup>
###xml 283 285 283 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 288 291 288 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 296 299 296 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink">68 </sup>
###xml 391 394 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 399 402 399 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 491 494 491 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink">68 </sup>
###xml 519 522 519 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">70 </sup>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11</xref>
###xml 644 647 644 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 652 655 652 655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 714 717 714 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 722 725 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 958 959 958 959 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 960 961 960 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 962 963 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 968 970 968 970 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1040 1042 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1078 1081 1078 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 1086 1089 1086 1089 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 1105 1107 1105 1107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 1115 1118 1115 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 1122 1125 1122 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 1129 1132 1129 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 1421 1423 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1662 1665 1662 1665 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 1753 1754 1753 1754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1816 1819 1816 1819 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 2097 2099 2097 2099 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 2107 2110 2107 2110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 686 691 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 838 843 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1180 1185 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1290 1297 <span type="species:ncbi:9606">patient</span>
###xml 1458 1466 <span type="species:ncbi:9606">patients</span>
###xml 1563 1571 <span type="species:ncbi:9606">patients</span>
###xml 1792 1795 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1796 1804 <span type="species:ncbi:9606">patients</span>
###xml 1865 1868 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1869 1877 <span type="species:ncbi:9606">patients</span>
###xml 2037 2042 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As we discussed above, analysis of the sequence of Tat for the presence of the (S/T)0P1K2(K/R)3 consensus motif for serine phosphorylation by CDK2 [27,28] showed that several sequences partially matched this motif: 16SQP(K/R)19 , 46 SYGR49 , 68SLSK71 . We determined conservancy of S16, S46 and S68 residues. We analyzed 158 sequences of Tat isolates deposited in the PubMed database. Both S16 and S46 were highly conserved with an occurrence of 100% or nearly 100% (Fig. 11). In contrast, S68 was present in 41%, and S70 - in 60% of the Tat isolates and all other serines were present in less than 50% (Fig. 11). This analysis indicates that S16 and S46 residues might be critical for HIV-1 replication. Because S16 and S46 residues were 100% conserved, it was not possible to analyze the effect of the mutation of these residues on the HIV-1 progression. We took advantage of the notion that a lysine or arginine present in the fourth position of the (S/T)0P1K2(K/R)3 consensus motif is critical for the recognition of the motif by CDK2 [27,28]. Thus we analyzed whether (K/R)19 and R49 residues within 16SQP(K/R)19 and 46 SYGR49 sequences of Tat were conserved among different HIV-1 isolates and whether mutations in these residues correlated with apparent progression of disease in the patient from whom the isolates were obtained. In this investigation, we studied 105 sequences of Tat deposited to PubMed database [34]. Of these, 55 were obtained from patients who were not on antiretroviral treatment and were classified as being healthy, and 50 were from patients who were classified as being ill and who were on antiretroviral treatment. We found that R49 was absolutely conserved, and thus no correlation could be obtained. In contrast, Table 2 shows that 29 (53%) of the "healthy" HIV patients had a (K/R)19 mutation compared to only 4 (8%) of the "ill" HIV patients (Pearson Chi-square correlation 24.312, df = 1; P < 0.001). This result suggests physiological importance of mutation of position 19 of Tat for progression of HIV-1 disease, and are consistent with the possibility that 16SQP(K/R)19 sequence is a putative CDK2 recognition site in Tat.
###end p 37
###begin p 38
###xml 17 20 17 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
Mutation of (K/R)19 residue sequence of Tat and Sickness Status
###end p 38
###begin p 39
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Serine residues at position 16 and 46 are highly conserved in Tat isolates</bold>
Serine residues at position 16 and 46 are highly conserved in Tat isolates. The 158 sequences of Tat isolates deposited to PubMed database were analyzed for the presence of serines at position 16, 23, 46, 61, 68, 70, 73, 74 and 75. Presence of a serine at the indicated position is presented as a percent of the total number of the isolates analyzed.
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 508 516 508 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 656 658 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 395 400 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 776 781 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our recent studies indicate that Tat's role in HIV-1 transcription is extremely complex and may not confine solely to the interaction with CDK9/cyclin T1. We have previously reported that Tat interacts directly or indirectly with host cell protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A). Tat binds to protein phosphatase-1 (PP1) and this binding is important for the induction of HIV-1 transcription by Tat [31,35]. Tat interaction with PP1 is intriguing as PP1 regulates CDK9 phosphorylation in vivo [36]. We recently showed that Tat binds to LIS1 protein, a product of lissencephaly gene which mutations cause a severe brain malformation [37]. LIS1 resembles the B-subunit of PP2A and interacts with the catalytic subunit of PP2A; and LIS1 expression induces HIV-1 transcription [38]. Thus Tat might also be able to interact with PP2A, although not directly with its catalytic subunit. The current study adds more complexity to the Tat function showing that Tat might undergo phosphorylation by CDK2/cyclin E.
###end p 41
###begin p 42
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 537 546 537 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 610 618 610 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 659 668 659 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1353 1355 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1717 1719 1717 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 134 139 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 354 359 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 407 412 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 649 654 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 805 810 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 902 907 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 994 999 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1018 1023 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1146 1151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1419 1423 <span type="species:ncbi:10090">mice</span>
###xml 1823 1828 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We hypothesized here that CDK2 affects HIV-1 transcription by phosphorylating Tat and that Tat phosphorylation might be important for HIV-1 transcription. We show here that Tat undergoes phosphorylation in vivo on serine residues, and that CDK2 is involved in this phosphorylation. Our findings also indicate that phosphorylation of Tat is important for HIV-1 transcription and the activation of integrated HIV-1 provirus. In our previous work we demonstrated that CDK2/cyclin E phosphorylates the C-terminal domain of RNA polymerase II in vitro [39-41]; that CDK2 was required for Tat-dependent transcription in vitro, and that CDK2 phosphorylates HIV-1 Tat in vitro [20,41]. CYC202 (R-roscovitine), a pharmacological inhibitor of CDK2, efficiently inhibited replication of wild type and HAART resistant HIV-1 mutants in T-cells, monocytes and PBMCs [42] indicating that CDK2 activity is required for HIV-1 replication. Recently we showed that siRNA-directed against CDK2 inhibits Tat-induced HIV-1 transcription and HIV-1 viral replication [33]. Thus our present study as well as our previous studies point to CDK2 as an important regulator of HIV-1 transcription. Until recently CDK2/cyclin E was considered to be essential for cell cycle progression and that CDK2 regulates G1/S transition by phosphorylating Rb-sequestering factors, including E2F [43]. Recent findings challenged this role of CDK2. CDK2 knock-out mice were viable [44], suggesting that CDK2 is dispensable for proliferation and survival of most cell types. Also, inhibition of CDK2 activity through expression of p27 Kip1, dominant-negative CDK2, antisense oligonucleotides or siRNA did not have an effect on growth of several tumor cell lines [45]. Therefore, not being essential for cellular viability, CDK2 might present a feasible target for anti-HIV-1 therapeutics.
###end p 42
###begin p 43
###xml 48 56 48 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Previous attempts to detect Tat phosphorylation in vivo were not successful [25]. It is possible that low level of Tat expression or fast dephosphorylation in the cells or during sample preparation may not allow easy detection of Tat phosphorylation. For example, in the early studies Ben Berkhout and his colleagues could only detect Tat expression in COS-7 cells but not in HeLa cells [46-48]. We found that expression of Flag-tagged Tat allowed higher levels of Tat expression especially with the adeno-virus mediated delivery. Treatment with okadaic acid, which inhibits phosphatases of the PPP-family including PP1 and PP2A [49], significantly enhanced Tat phosphorylation (Fig. 3), suggesting that Tat may be dynamically dephosphorylated by a cellular PPP-type phosphatase. When we inhibited PP1 by over expression of the central domain of nuclear inhibitor of PP1 (NIPP1) [31] we did not detect changes in Tat phosphorylation (data not shown). Thus PP2A rather than PP1 is a candidate phosphatase to dephosphorylate Tat.
###end p 43
###begin p 44
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Our analysis showed that inhibition of CDK2 expression by siRNA substantially blocked Tat phosphorylation and prevented association of Tat with CDK2. Although these findings suggest that CDK2 might directly phosphorylate Tat, we also cannot rule out a possibility that inhibition of CDK2 reduces the activity of another kinase that in turn might be involved in Tat phosphorylation. Finding that Tat co-migrates with CDK2 on glycerol gradient and also co-precipitated with CDK2 confirms our previous observation that Tat-associated kinase activity contained CDK2 [41]. CDK2-directed siRNA significantly reduced association of CDK2 to Tat, probably by reducing the amount of CDK2 available to interact with Tat.
###end p 44
###begin p 45
###xml 55 62 55 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 97 99 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 103 106 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 111 114 111 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink">41 </sup>
###xml 117 120 117 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">43 </sup>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 269 272 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 277 280 277 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 328 331 328 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 351 354 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">41 </sup>
###xml 357 360 357 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">43 </sup>
###xml 400 403 400 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">41 </sup>
###xml 406 409 406 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">43 </sup>
###xml 628 629 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 644 647 644 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">23 </sup>
###xml 650 652 650 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">37</sup>
###xml 667 670 667 670 <sup xmlns:xlink="http://www.w3.org/1999/xlink">51 </sup>
###xml 1008 1010 1008 1010 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 1018 1021 1018 1021 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 1025 1027 1025 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46</sup>
###xml 1031 1034 1031 1034 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 1069 1070 1069 1070 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 1071 1072 1071 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1073 1074 1073 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1079 1081 1079 1081 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1186 1188 1186 1188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1395 1397 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
We found that Tat is phosphorylated on serine residues in vivo. We previously suggested that the 16SQPK19 and K41 x L43 sequences of Tat interact with CDK2 and cyclin E respectively, and that S16 is phosphorylated by CDK2 [20]. In the present study we found that both S16 and S46 of Tat are potential phosphorylation sites. As S46 is adjacent to the K41 x L43 sequence of Tat, it is likely that the K41 x L43 sequence participates in binding to CDK2 rather than to cyclin E, as we originally suggested. Interestingly, recombinant CDK2/cyclin E only phosphorylated full length Tat 1-72 but not the 15 amino acid peptides of Tat, 9EPWKHPGSQPKTACN23 or 37CFTTKGLGISYGRKK51 (AIDS Research and Reference Reagents Program, NIH), containing only the phosphorylation sites (data not shown), which may indicate a requirement of additional sequences of Tat for its interaction with CDK2/cycline E. Another explanation is that full length Tat creates a favorable conformation for phosphorylation by CDK2. The sequences 16SQP(K/R)19 and 46SYGR49 only partially match the CDK2 (S/T)0P1K2(K/R)3 phosphorylation motif. Although the catalytic efficiency of CDK2-cyclin A is impaired 2000-fold, when Pro1 is substituted with Ala in a short synthetic peptide substrate, physiological substrates for both CDK2-cyclin A and CDK2-cyclin E often contain phosphorylation motifs replaced with sub optimal determinants [28]. In such sub optimal substrates phosphorylation is enhanced by a cyclin-binding motif that compensates for otherwise poor catalysis [28]. Therefore, binding of cyclin E still might be important for efficient phosphorylation of Tat by CDK2.
###end p 45
###begin p 46
###xml 40 43 40 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 289 292 289 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 383 386 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 391 394 391 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 543 546 543 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 629 632 629 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1251 1254 1251 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 1260 1263 1260 1263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8A</xref>
###xml 1468 1470 1468 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1735 1737 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1932 1934 1932 1934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 325 330 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 453 458 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 845 850 <span type="species:ncbi:4932">yeast</span>
###xml 916 921 <span type="species:ncbi:4932">yeast</span>
###xml 1384 1388 <span type="species:ncbi:4530">Rice</span>
Using mutation analysis, we found that S16 and S46 are equally important for activation of integrated proviral DNA. The single point mutants did not show a significant level of activation, and the double mutant Tat was completely inactive in HLM-1 cells. In contrast, mutation of S16 and S46 moderately reduced activation of HIV-1 transcription from the episomal promoter. Thus Tat S16 and S46 residues are important for transcription of a full genomic HIV-1 template containing natural chromatin structure. The effect of alanine mutation of S46 is at variance with the previously published observation that alanine mutation of S46 induces Tat-transactivation [50]. We did not see an increase of Tat transactivation with all mutants tested. Thus we cannot explain this discrepancy. Tat was proposed to form aggregates in the nucleus [51]. Using yeast two-hybrid system, we found no evidence that Tat forms dimers in yeast cells (not shown). Therefore, it remains to be determined why Tat should undergo phosphorylation to be fully active as a transcriptional activator. We did not detect a difference between WT and mutant Tat in ability to bind to TAR RNA (not shown). We observed an increase in the expression of untagged Tat with mutations in the S16 or Ser46 Tat residues and particular of the double mutant of Tat (Fig. 8A). An increase in Tat expression was observed earlier by Rice and Carlotti with a mutant of Tat that lacked first 36 N-terminal amino acids [50]. Thus the amount of Tat expressed in the cells might be stringently controlled and the excess of Tat might have a negative effect on Tat transactivation. Another possibility is that Tat may need to undergo non-proteolytic ubiquitination by Hdm2 ubiquitin ligase [22] to be fully active as a transactivator. It is possible that Tat phosphorylation may facilitate ubiquitination of Tat by Hdm2 similar to phosphorylation-dependent ubiquitination of p53 by Hdm2 [52].
###end p 46
###begin p 47
###xml 150 153 150 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16 </sup>
###xml 158 161 158 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46 </sup>
###xml 271 273 271 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">16</sup>
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">46</sup>
###xml 294 297 294 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 328 331 328 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink">49 </sup>
###xml 413 416 413 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 492 495 492 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 663 666 663 666 <sup xmlns:xlink="http://www.w3.org/1999/xlink">19 </sup>
###xml 360 365 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 467 472 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 597 602 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Analysis of Tat sequences available in the PubMed showed that Tat isolates contain from 4 to 11 serine residues. In addition to the highly conserved S16 and S46 residues, Tat contains less conserved serines at positions 23, 61, 62, 68, 70, 73, 74 and 75. Analysis of the 16SQP(K/R)19 and 46SYGR49 sequences of Tat, showed that R49 is conserved among different HIV-1 isolates. Interestingly, mutations in the (K/R)19 residue showed correlation with non-progression of HIV-1 disease. Thus (K/R)19 residue which is part of a putative CDK2 recognition site in Tat, may be important for progression of HIV-1 disease. Future study will address whether mutation of (K/R)19 residue is important for phosphorylation of Tat by CDK2 and whether mutations in this residue affect viral replication.
###end p 47
###begin p 48
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 273 280 273 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 151 156 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Taken together, our findings indicate that Tat is phosphorylated in vivo and that phosphorylation of Tat is important for the activation of integrated HIV-1 provirus. Our finding also indicates that CDK2 associates with Tat and thus is likely to phosphorylate Tat directly in vivo. Our findings open the door to the evaluation of the potential efficiency of presently available CDK2 inhibitors and specifically designed future inhibitors to disrupt CDK2-Tat association.
###end p 48
###begin title 49
Methods
###end title 49
###begin title 50
Materials
###end title 50
###begin p 51
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 958 975 954 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 1101 1103 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 117 123 <span type="species:ncbi:9986">rabbit</span>
###xml 136 141 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 931 936 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 958 974 <span type="species:ncbi:562">Escherichia coli</span>
293T cells and COS-7 cells were purchased from ATCC (Manassas, VA). HeLa-MAGI cells [53], HLM-1 cells [54], anti-Tat rabbit polyclonal (HIV-1 BH10 Tat antiserum, [55]) and monoclonal (NT3 2D1.1, courtesy of Dr. Jonathan Karn) antibodies were received from the AIDS Research and Reference Reagents Program (NIH). Anti-Flag monoclonal antibodies, anti-alpha-tubulin antibodies, protein (G) and protein (A) agarose and okadaic acid were purchased from Sigma (Atlanta, GA). All radioactive reagents were purchased from GE Health Care Life Sciences. The 3,3'-diaminobenzidine enhanced liquid substrate system for membrane ELISA (DABM) was purchased from Sigma (St Louis, MO). Antibodies for CDK2, CDK9, cyclin T1 and cyclin T2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against RNAPII were from Babco. Anti-Brd4 and anti-HEXIM1 antibodies were a gift from Dr.Q. Zhou (University of California, Berkeley). HIV-1 Tat was expressed in Escherichia coli and purified on Aquapore RP-300 column (Applied Biosystems, Foster City, CA) by reverse-phase chromatography as we described [20].
###end p 51
###begin title 52
Plasmids
###end title 52
###begin p 53
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 127 130 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Tat expression plasmid was a gift from Dr. Ben Berkhout (University of Amsterdam) [48]. The Flag-Tat was cloned into the adeno-CMV-link vector as described below and verified by sequencing. The S16A and S46A mutations of the sequence of Tat were made according to the Quick-Change site-directed mutagenesis protocol of Stratagene, using the appropriate primers and templates. The sequences of the DNA constructs were verified by sequencing using a commercial service from Macrogen (Seoul, Korea).
###end p 53
###begin title 54
CDK2/cyclin E purification
###end title 54
###begin p 55
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 855 872 849 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
CDK2 and cyclin E were purified from lysates of Sf9 insect cells infected with baculoviruses producing CDK2 and cyclin E. Proteins were purified essentially as described earlier [56]. Briefly, 1 ml of cells (from 250 ml of culture) was lysed with 16 ml of lysis buffer (50 mM Tris-HCl, pH 8.0, 10 mM 2-mercaptoethanol, 10% glycerol and with PMSF), homogenized on ice and centrifuged at 45,000 g for 1 hr at 4degreesC. Supernatant was loaded on Mono-Q 10/10 column (Amersham, USA). Two separate cell cultures, one infected with CDK2-expressing baculovirus and the other one infected with cyclin E-expressing baculovirus were used for purification. The Mono-Q fractions containing CDK2 or cyclin E were mixed 1:1 and loaded onto Superdex column (Sephadex H200, Amersham, USA). Purity of CDK2/cyclin E was checked on 12% PAGE followed by Coomassie staining (Additional file 1). We also analyzed the Superdex fractions by immunoblotting with andti-CDK2 antibodes and assayed their enzymatic activity using histone H1 and purified Tat proteins as substrates. Fractions containing CDK2/cyclin E were concentrated using Microcon tubes (Amicon, USA).
###end p 55
###begin title 56
In vitro kinase assay
###end title 56
###begin p 57
###xml 118 119 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 215 217 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
CDK2 kinase assays were performed at 30degreesC for 30 min in kinase assay buffer (50 mM HEPES-KOH, pH 7.9, 10 mM MgCl2, 6 mM EGTA, 2.5 mM DTT) containing histone H1 or purified Tat protein, 200 muM ATP and (gamma-P32)ATP. A mixture was incubated for 30 min at 30degreesC, reaction was stopped with 8 mul of 4x SDS buffer and resolved on 12% PAGE.
###end p 57
###begin title 58
Immunoprecipitation of CDK2 and kinase assay with Tat
###end title 58
###begin p 59
###xml 573 575 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 224 230 <span type="species:ncbi:9986">rabbit</span>
###xml 324 330 <span type="species:ncbi:9986">rabbit</span>
293T cells were transfected with CDK2-directed or non-targeting siRNA. At 48 hours after transfection cells were lysed in whole cell lysis buffer. About 50 mug of protein lysate was subjected to precipitation with anti-CDK2 rabbit antibodies (600 ng/IP) on 40 mul protein A agarose beads (50% slurry) (Sigma). As a control, rabbit preimmune serum was used. Precipitation was carried out for 2 hrs at 4degreesC. The beads were washed with TNN buffer, then with TTK buffer and supplemented with 20 mul of kinase mixture containing TTK buffer, 100 muM ATP, 0.5 muCi of gamma-(32P)ATP and 1 mug of purified Tat. The kinase reaction was carried out for 15 min at 30degreesC, reaction was stopped with 8 mul of 4x SDS-loading buffer and resolved on 12% Tris-Tricine gel. The gel was stained with Coomassie blue, dried and exposed to Phosphor Imager screen.
###end p 59
###begin title 60
Fractionation of cellular lysates on glycerol gradient
###end title 60
###begin p 61
293T cells were infected with Adeno-Tat virus with MOI 1, and incubated overnight. The cells in 100 mm plate were lysed with 0.5 ml of whole cell lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) supplemented with protease cocktail (Sigma) and RNasin (Amersham). Cell lysates were clarified by centrifugation for 30 min at 10,000 g and loaded on top of 10% to 30% glycerol (9 ml) gradient. Glycerol gradient buffer contained 20 mM HEPES-KOH, pH 7.9, 150 mM KCl, 200 muM EDTA
###end p 61
###begin p 62
The gradient was spun in SW 41Ti rotor (Beckman) at 38,000 rpm for 18 hours. Fractions (0.5 ml) were collected through a needle inserted to the bottom of the tube and analyzed by Immunoblotting.
###end p 62
###begin title 63
Tat trypsinization and chromatographic separation of peptides
###end title 63
###begin p 64
###xml 206 208 205 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Non-phosphorylated and phosphorylated Tat were resolved by 15% Tris-Tricine SDS-PAGE. A gel piece containing Tat was crushed and incubated with 1 mug of porcine trypsin (Promega, Madison, WI) in 0.1 M NaHCO3 (pH 7.9) overnight at 37degreesC. The extracted peptides were lyophilized, dissolved in 0.1% TCA and separated by reverse-phase chromatography on a muRPC C2/C18 ST 4.6/100 column (Amersham Pharmacia Biotech) using AKTA purifier (AmershamPharmaciaBiotech). Eluent A was 0.1% TCA in water and eluent B was 0.1% TCA in 90% acetonitrile. The gradient was 5% B for 2 column volumes (CVs), 5-50% B for 20 CVs, 50-100% B for 12 CVs and 100% B for 4 CVs. The flow rate was 0.5 ml/min.
###end p 64
###begin title 65
MALDI-TOF mass spectrometry and peptide sequencing
###end title 65
###begin p 66
Fractions from the HPLC separation described above were lyophilized. Multiple peptide sequences were determined in a single run by Applied Biosystems Maldi-TOF/TOF 4700 proteomics analyzer (25-30,000 resolution in reflectron mode, 5 ppm accuracy with IS, subfmole sensitivity for peptide mass fingerprints (PMF), fmole sensitivity for PSD/CID capacity of >36,000 PMF per 24 hours). Data were analyzed utilizing a local multi-processor installation of MASCOT MS PMF and MS/MS PSD, CID peptide identification software. GPS also supports an integrated MS-MS/MS mode and a chromatographic separation mode with SEQUEST-like capability.
###end p 66
###begin title 67
Preparation of Adeno-Tat
###end title 67
###begin p 68
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 137 142 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 213 216 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 269 274 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The E1-deleted recombinant Ad carrying Tat was generated as previously described [31]. Briefly, a cDNA fragment encoding the full length HIV-1 Tat protein was cloned into the plasmid pCXN was subcloned in the pAd.CMV link plasmid. The Tat-coding DNA corresponds to the HIV-1 isolate P9.3 from United Kingdom (Accession number AF324447). The DNA sequence is ATGGACTACAAGGACGACGA TGACAAAGAA TTCATGGAGC CAGTAGATCCTAGACTAGAG CCCTGGGAGC ATCCAGGAAG TCAGCCTAAG ACTGCTTGTACCCCTTGCTA TTGTAAAAAG TGTTGCTTTC ATTGCCAAGT TTGTTTCACAACAAAAGGCT TAGGCATCTC CTATGGCAGG AAGAAGCGGA GACAGCGACGAAGAGCTCCT CAAGACAGTC AGACTCATCA GGCTTCTCTA TCAAAGCAATCCCTACCCCA AACCCAGAGG GACTCGACAG GCCCGGAAGA ATCGAAGAAGGAGGTGGAGA GCAAGGCAGAGACAGATCGA TTCGATTA. It corresponds to the protein sequence of Tat containing Flag epitope at its N-terminus-MDYKDDDDKEFMEPVDPRLEPWEHPGSQPKTACTPCYCKKCCFHCQVCFTTKGLGISYGRKKRRQRRRAPQDSQTHQASLSKQSLPQTQRDSTGPEESKKEVESKAETDRFD. pAd.CMVlink and Cla I digested adenoviral DNA were co-transfected into HEK293 cells at a ratio of 3:1 by calcium phosphate precipitation to allow the recombination. The virus was purified through three rounds of plaque-purification. Viruses were replicated in HEK293 cells and were purified from a cell lysate by two rounds of CsCl density gradient centrifugation. The purified virus was desalted on a Bio-Gel P-6 desalting column (Bio-Rad Laboratories, Hercules, CA) equilibrated with PBS. The titer of the virus preparation was determined both by absorbency at 260 nm and by plaque assay. The particle to plaque forming unit ratio was less than 100. Purified viruses were suspended in PBS at the desired concentrations.
###end p 68
###begin title 69
Tat phosphorylation in vivo
###end title 69
###begin p 70
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 529 531 529 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1452 1454 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
HeLa cells were infected with recombinant Adenovirus carrying Flag-tagged Tat prepared as we described [31]. The purified virus had a particle to plaque forming unit (Pfu) ratio of less than 100. We added approximately 10 Pfu per cell to achieve high level of Tat expression in infected HeLa cells. At 48 hours post infection the media was changed for 1 hour to a phosphate-free DMEM media (Life Technologies, Rockville, MD) containing no serum. Then the media was changed to phosphate-free DMEM supplemented with 0.5 mCi/ml of (32P)-orthophosphate and cells were further incubated for 2 hours at 37degreesC. Where indicated, 1 muM okadaic acid (Sigma) was added to block cellular PPP-phosphatases. Cells were washed with PBS and lysed in whole cell lysis buffer (50 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) supplemented with protease cocktail (Sigma). After 10 min on ice, cellular material was scraped and then centrifuged at 14,000 rpm, 4degreesC for 30 min. The supernatant was recovered and immediately used for immunoprecipitation. Tat was precipitated with anti-Flag monoclonal antibodies coupled to protein G agarose and with polyclonal anti-Tat antibodies coupled to protein A agarose for 2 h at 4degreesC in a TNN Buffer containing 50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, and 1% NP-40. The immunoprecipitated Tat was recovered by heating for 2 min at 100degreesC in Tricine SDS-loading buffer, resolved on 15% Tris-Tricine SDS-PAGE [32] and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Allen, TX). The membrane was analyzed with anti-Tat monoclonal antibodies using 3,3'-Diaminobenzidine enhancer system (Sigma) and was also exposed to Phosphor Imager screen (Packard Instruments, Wellesley, MA).
###end p 70
###begin title 71
Phosphoamino acid analysis
###end title 71
###begin p 72
###xml 486 488 480 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 533 535 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
The analysis was carried out on the Hunter thin layer peptide mapping electrophoresis system (CBS, Del Mar, CA) according to the manufacturer's recommendations. Briefly, phosphorylated Tat, prepared as described above was resolved on 15% SDS-Tris-Tricine PAGE and the gel was dried on a Whatman paper. The portion of the gel containing Tat was excised, rehydrated and treated overnight with trypsin to elute Tat. The eluted peptides were boiled in 5.7 M HCl at 110degreesC to liberate (32P)-labeled phospho-amino acids as described [57]. After the hydrolysis, the sample was lyophilized and resuspended in the buffer for pH 1.9 electrophoresis also containing the phosphoamino acid standards at 0.06 mg/ml. The sample was resolved by thin-layer electrophoresis on a cellulose plate (CBS, Del Mar, CA) at pH 1.9 in the first direction and at pH 3.5 in the second direction. Cold standards were visualized by staining the plate with 0.25% ninhydrine dissolved in ethanol. Positions of labeled phosphoamino acids were analyzed with Phosphor Imager (Packard Instruments, Wellesley, MA).
###end p 72
###begin title 73
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transfection and HIV-1 detection from HLM1 cells
###end title 73
###begin p 74
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 389 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 930 936 <span type="species:ncbi:9913">bovine</span>
HLM-1cells were derived from HeLa-T4+ cells integrated with one copy of HIV-1 genome containing a Tat-defective mutation. The mutation was introduced as a triple termination linker (TTL) at the first AUG of Tat gene [54]. HLM-1 cells are negative for virus particle production HLM1 cells are negative for virus particle production. HLM1 cells can be induced to express non-infectious HIV-1 particles after transfection with Tat cDNA, or by treatment with mitogens such as TNF-alpha or sodium butyrate. HLM1 cells were grown in DMEM media containing 100 mug/ml of G418, plus 1% streptomycin, penicillin antibiotics and 1% L-Glutamine (Gibco/BRL). The cells grown up to 75% confluence were transfected with Tat expression vectors, including wild type Tat, S16A, S46A, and S16A/S46A mutant Tat plasmids using the calcium phosphate method. The transfected cells were washed after four hrs and fresh complete DMEM media with 10% fetal bovine was added for the remainder of the experiment. The p24 gag antigen was detected in the supernatants of transfected cells using a standard ELISA kit (Abbott).
###end p 74
###begin title 75
siRNA treatment
###end title 75
###begin p 76
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
CDK2-directed siRNA pool (M-003236-03-005) and negative control pool (D-001206-13-05) were purchased from Dharmacon (Dallas, TX). The siRNAs were transfected at final concentration of 100 nM using Lipofectamin reagent (Invitrogen) according to the manufacturer's recommendations. The siRNAs were incubated with cells for 2 days before cells were labeled with 32P or lysed for Western blotting analysis.
###end p 76
###begin title 77
Competing interests
###end title 77
###begin p 78
The author(s) declare that they have no competing interests.
###end p 78
###begin title 79
Authors' contributions
###end title 79
###begin p 80
###xml 49 58 49 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 238 246 238 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 247 249 247 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 727 735 727 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 578 583 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TA purified recombinant CDK2/cyclin E, performed in vitro Tat phosphorylation, carried out the experiments with the CDK2-directed siRNA, CDK2-Tat precipitation experiments, Western blot analysis of glycerol gradients and also helped with in vivo (32P) phosphorylation experiments and with Tat mutagenesis. RB and ZK carried out experiments with live virus. MJ prepared adeno-Tat virus, helped to analyze the expression of Tat in cultured cells and prepared samples for MALDI-TOF analysis. MJ and SN were also running glycerol gradients. SC performed statistical analysis of the HIV-1 isolates. EE performed MALDI TOF analysis of Tat peptides. WS, VRG and FK participated in the design and discussion of the study. SN performed in vivo Tat phosphorylation experiments, phosphoaminoacid analysis of Tat and Tat mutagenesis, and also performed general control and coordination of the study. All authors read and approved the manuscript.
###end p 80
###begin title 81
Supplementary Material
###end title 81
###begin title 82
Additional File 1
###end title 82
###begin p 83
Purification of CDK2/cyclin E. Mixed mono Q fractions of CDK2 and cyclin E (Mono Q lane) were purified on Superdex column. Fractions 37, 39, 41, 43, and 45 were analyzed for the presence of CDK2 and cyclin E by Coumassie staining.
###end p 83
###begin p 84
Click here for file
###end p 84
###begin title 85
Acknowledgements
###end title 85
###begin p 86
This work was supported by NIH Grant R21 AI 156973-01 (to S. N.), by NHLBI Research Grant UH1 HL03679 from the National Institutes of Health and The Office of Research on Minority Health. This work was also supported by grant 2 G12 RR003048 from the RCMI Program, Division of Research Infrastructure, National Center for Research Resources, NIH (to W.S.) and by NIH grants AI44357, AI43894 to FK, and Research Enhancement Fund (REF, GW) to Akos Vertes and F. Kashanchi. We thank Dr. Eric Eccleston for help with MALDI-TOF. The authors would like to thank members of Dr. Victor Gordeuk's laboratory at the Center for Sickle Cell Disease at Howard University for valuable discussions. We also thank Dr. Ajit Kumar for permission to use Hunter thin layer peptide mapping electrophoresis system. We thank Qiang Zhou (University of California, Berkeley) for the gift of ant-Brd4 and HEXIM1 antibodies.
###end p 86
###begin article-title 87
Tat gets the "green" light on transcription initiation
###end article-title 87
###begin article-title 88
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV Tat, its TARgets and the control of viral gene expression
###end article-title 88
###begin article-title 89
###xml 48 53 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the F-box protein beta-TrCP
###end article-title 89
###begin article-title 90
###xml 33 36 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection
###end article-title 90
###begin article-title 91
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein
###end article-title 91
###begin article-title 92
###xml 22 57 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The conserved core of human immunodeficiency virus type 1 Nef is essential for association with Lck and for enhanced viral replication in T-lymphocytes
###end article-title 92
###begin article-title 93
###xml 37 65 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Site-specific phosphorylation of the human immunodeficiency virus type-1 Rev protein accelerates formation of an efficient RNA-binding conformation
###end article-title 93
###begin article-title 94
###xml 102 137 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation
###end article-title 94
###begin article-title 95
###xml 55 60 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs
###end article-title 96
###begin article-title 97
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effects of integration and replication on transcription of the HIV-1 long terminal repeat
###end article-title 97
###begin article-title 98
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Kinetics of HIV-1 long terminal repeat trans-activation. Use of intragenic ribozyme to assess rate-limiting steps
###end article-title 98
###begin article-title 99
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Direct interaction of human TFIID with the HIV-1 transactivator tat
###end article-title 99
###begin article-title 100
Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor
###end article-title 100
###begin article-title 101
###xml 8 11 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 tat transcriptional activity is regulated by acetylation
###end article-title 102
###begin article-title 103
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity
###end article-title 103
###begin article-title 104
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 75 80 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones
###end article-title 104
###begin article-title 105
###xml 4 7 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II
###end article-title 105
###begin article-title 106
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 155 160 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter
###end article-title 106
###begin article-title 107
Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF
###end article-title 107
###begin article-title 108
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter
###end article-title 108
###begin article-title 109
###xml 38 73 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression
###end article-title 109
###begin article-title 110
###xml 19 54 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR
###end article-title 110
###begin article-title 111
###xml 43 78 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Phosphorylation of the rev gene product of human immunodeficiency virus type 1
###end article-title 111
###begin article-title 112
###xml 28 56 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase
###end article-title 112
###begin article-title 113
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase
###end article-title 113
###begin article-title 114
Substrate specificity of CDK2-cyclin A. What is optimal?
###end article-title 114
###begin article-title 115
Phosphopeptide detection and sequencing by matrix-assisted laser desorption/ionization quadrupole time-of-flight tandem mass spectrometry
###end article-title 115
###begin article-title 116
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nuclear protein phosphatase-1 regulates HIV-1 transcription
###end article-title 116
###begin article-title 117
Electrophoretic separation of multiprotein complexes from blood platelets and cell lines: technique for the analysis of diseases with defects in oxidative phosphorylation
###end article-title 117
###begin article-title 118
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
RNA interference directed to CDK2 inhibits HIV-1 transcription
###end article-title 118
###begin article-title 119
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nuclear targeting of protein phosphatase-1 by HIV-1 TAT protein
###end article-title 119
###begin article-title 120
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Dephosphorylation of CDK9 by protein phosphatase 2A and protein phosphatase-1 in Tat-activated HIV-1 transcription
###end article-title 120
###begin article-title 121
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat interacts with LIS1 protein
###end article-title 121
###begin article-title 122
###xml 37 42 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Inhibition of PP2A by LIS1 increases HIV-1 gene expression
###end article-title 122
###begin article-title 123
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 37 72 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymerase II and induces CAK activity
###end article-title 123
###begin article-title 124
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cell cycle-dependent stimulation of the HIV-1 promoter by Tat-associated CAK activator
###end article-title 124
###begin article-title 125
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription
###end article-title 125
###begin article-title 126
###xml 32 37 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Antiviral activity of CYC202 in HIV-1 infected cells
###end article-title 126
###begin article-title 127
Control of the G1/S transition
###end article-title 127
###begin article-title 128
Driving the cell cycle to cancer
###end article-title 128
###begin article-title 129
Proliferation of cancer cells despite CDK2 inhibition
###end article-title 129
###begin article-title 130
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication
###end article-title 130
###begin article-title 131
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation
###end article-title 131
###begin article-title 132
###xml 68 96 <span type="species:ncbi:12721">human immunodeficiency virus</span>
A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus
###end article-title 132
###begin article-title 133
Okadaic acid, useful tool for studying cellular processes
###end article-title 133
###begin article-title 134
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein
###end article-title 134
###begin article-title 135
###xml 42 70 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus
###end article-title 135
###begin article-title 136
Regulation of ubiquitination and degradation of p53 in unstressed cells through C-terminal phosphorylation
###end article-title 136
###begin article-title 137
###xml 51 79 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
###end article-title 137
###begin article-title 138
###xml 69 72 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Induction of developmentally programmed cell death and activation of HIV by sodium butyrate
###end article-title 138
###begin article-title 139
###xml 20 48 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Trans-activation of human immunodeficiency virus gene expression is mediated by nuclear events
###end article-title 139
###begin article-title 140
###xml 36 41 <span type="species:ncbi:9606">human</span>
Purification and crystallization of human cyclin-dependent kinase 2
###end article-title 140
###begin article-title 141
Detection and quantification of phosphotyrosine in proteins
###end article-title 141

